Iulia Diaconu

Biochemistry, Genetics and Molecular Biology · Life Sciences

29h-index3.3kcitations152works0.72yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Virus-based gene therapy research(126), CAR-T cell therapy research(90), Cancer Research and Treatments(67), Viral Infectious Diseases and Gene Expression in Insects(64), Immunotherapy and Immune Responses(12)

Publications152 total

Analysis of risk factors for neurological complications of SARS-CoV-2 infection: focus on chronic fatigability
Revista Medico-Chirurgicala·2025
417 Design of programmable immune reactive cells (PIRCs) with precision type I interferon and cytotoxicity response in solid tumors
Regular and Young Investigator Award Abstracts·2024Open Access
COVID-19 neurological manifestations - the experience of a tertiary hospital from Northeastern Romania
Revista Medico-Chirurgicala·2024· 2 citedOpen Access
442-E A novel targeted, type I interferon producing, innate lymphocyte therapy with potent anti-tumor activity
2023Open Access
Supplementary Data from T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
2023Open Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 3 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 4 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure Legend from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Table 1 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Figure 2 from Antiviral and Antitumor T-cell Immunity in Patients Treated with GM-CSF–Coding Oncolytic Adenovirus
2023Open Access
Supplementary Data from Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1
2023Open Access
Supplementary Data from T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
2023Open Access
Data from Targeted Chemotherapy for Head and Neck Cancer with a Chimeric Oncolytic Adenovirus Coding for Bifunctional Suicide Protein FCU1
2023Open Access
Supplementary Data from T-Cell Receptor Stimulation Enhances the Expansion and Function of CD19 Chimeric Antigen Receptor–Expressing T Cells
2023Open Access
page 1 of 8Next →

Frequent Co-authors

Akseli Hemminki(33), Vincenzo Cerullo(32), Anna Kanerva(24), Lotta Kangasniemi(14), Sophie Escutenaire(14), Sari Pesonen(13), Minna Oksanen(13), Timo Joensuu(12), Leena Laasonen(11), Saila K. Pesonen(10), Anniina Koski(9), Petri Nokisalmi(9), Kilian Guse(9), Liisa Holm(9), Kaarina Partanen(9), Sari Pesonen(9), Gianpietro Dotti(8), Elina Haavisto(8), Aila Karioja‐Kallio(8), Maria Rajecki(7)